Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
(NYSE: LLY) and Novo Nordisk (NYSE: NVO) , have lagged broader equities, though the latter has performed substantially worse than the former. Still, analysts predict that this therapeutic area will soar over the next decade, and there is a good chance these two will maintain their edge over their peers given their pipelines. But which one is a better buy? Comparing their weight loss portfolios Eli Lilly's weight loss medicine, Zepbound, and Novo Nordisk's Wegovy have gone head-to-head in a clinical trial. The former emerged victorious, leading to a mean weight loss of 20.2% compared to the latter's 13.7% in the 72-week study. It's no wonder, then, that Zepbound has been gaining significant traction and now holds the lead in this market, despite Wegovy being approved more than two years before it. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology N
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Vaxess Technologies raises $50m, rebrands to Terrestrial Bio [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market [Seeking Alpha]Seeking Alpha
- Hims & Hers shifts business model after Novo deal [Yahoo! Finance]Yahoo! Finance
- FDA Approval Of Awiqli Adds New Dimension To Novo Nordisk Story [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/26/26 - Form 6-K
- NVO's page on the SEC website